Enzymatica AB: The board of directors in Enzymatica has resolved on a directed share issue of SEK 40.3 million

Regulatory information
Press release
Lund on August 30, 2016

Press release
Lund on August 30, 2016
                                                                                         
The board of directors in Enzymatica has resolved on a directed share issue of SEK 40.3 million

The board of directors in Enzymatica AB (publ) (the "Company") has on August 30, 2016 resolved to, pursuant to the authorization granted by the Annual General Meeting held on 25 May 2016, issue 17,500,000 new shares with deviation from the shareholders' pre-emptive rights. The share issue is directed to Abanico Invest AB (Mats Andersson), Fibonacci Asset Management AB (Björn Algkvist) and RoosGruppen AB (Håkan Roos), a limited group of new and existing long-term investors.

The subscription price of SEK 2.30 per share corresponds to a discount of approximately 4.2 per cent compared to one month volume weighted average price on Nasdaq First North Stockholm, and the board of directors considers the subscription price to be in accordance with the market based on the current industry and market conditions, as well as in relation to the volume and objective of the share issue. The Company has been engaged in discussions with the share subscribers and the reasons to deviate from the existing shareholders' pre-emptive rights are due to the possibility to raise new working capital in a time and cost efficient way in order to strengthen the Company's cash position and to create a financial stability. The new share issue increases the number of shares in the Company with 17,500,000 shares from 73,387,808 shares to 90,887,808 shares in total, which corresponds to a dilution of approximately 19 per cent, and increases the share capital by SEK 700,000.23 from SEK 2,935,513.27 to SEK 3,635,513.50 in total.

Statement from Fredrik Lindberg, CEO Enzymatica AB (publ):
We are very pleased to have attracted these long-term and experienced investors. With this capital injection we are pursuing our financing plan and it creates a financial stability for the business and our international expansion, says Fredrik Lindberg.

For more information, please contact:

Fredrik Lindberg, CEO Enzymatica AB
Tel: +46 708-86 53 70 | E-post: fredrik.lindberg@enzymatica.com

This information is information that Enzymatica AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 0920 CET on August 30, 2016.

About Enzymatica AB
Enzymatica is a life science company who develops and sells medical device products against infectious-related diseases. Over a short period the company has developed a unique oral spray for colds, ColdZyme®, and launched it on six markets. The product has become one of the leading articles for colds in Swedish pharmacies. Enzymatica's strategy is to continue growing by strengthening its position in existing markets and to expand to more geographical markets through well-established partners. The company is headquartered in Lund, Sweden and is listed on Nasdaq First North. For more information, please visit www.enzymatica.com.   

Enzymatica's certified advisor is Erik Penser Bankaktiebolag.

Enzymatica cares about your privacy and processes your personal data in accordance with the EU’s General Data Protection Regulation. For more information about how we handle your personal information, and what rights you have, please refer to our personal data processing document here.